Cardio Diagnostics Holdings, Inc. (CDIO) stock
CDIONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31Also trades as CDIOW
$1.87−0.05 (-2.60%)
Close on Nov 12, 2026Market cap $5.53MP/E –Yield –
Cardio Diagnostics ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Cardio Diagnostics's ebitda for the twelve months ending Sep 30, 2026 was -$6.45M. For fiscal 2025 it was -$6.42M. The highest annual figure on record is -$604.45K in fiscal 2021.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.42M | – |
| FY2024 | Dec 31, 2024 | -$8.35M | – |
| FY2023 | Dec 31, 2023 | -$7.22M | – |
| FY2022 | Dec 31, 2022 | -$4.53M | – |
| FY2021 | Dec 31, 2021 | -$604.45K | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.72M | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.49M | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.78M | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.59M | – |
| Q4 FY2024 | Dec 31, 2024 | -$1.51M | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.40M | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.28M | – |
| Q1 FY2024 | Mar 31, 2024 | -$4.15M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.54M | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.44M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.55M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.70M | – |
| Q2 FY2022 | Jun 30, 2022 | -$782.96K | – |
| Q1 FY2022 | Mar 31, 2022 | -$223.09K | – |
See a number that looks wrong?